M·CAM, Inc. releases Patently Obvious® on iBio, Inc.

Date:  Fri, 2012-03-09

CHARLOTTESVILLE, VA – March 9, 2012 – M·CAM, Inc. released its Patently Obvious® report today on iBio, Inc.

On February 29, 2012, iBio, Inc., a pharmaceutical company, announced the issuance of a patent on an influenza virus vaccine. As a result, iBio’s stock increased over 10% during a time when the overall market was declining – proving, yet again, that intangible assets influence marginal value (or at least investor emotion and sentiment). This announcement and subsequent rise in iBio’s stock value is particularly interesting considering Fraunhofer USA, Inc. was, at least at the time, listed as the patent’s inventor and assignee.

M·CAM’s Patently Obvious® is a weekly report providing visibility into potentially unconsidered alternatives, including art in the public domain, to patent holdings across a variety of technology areas.

M·CAM, Inc. is a global, full-service intellectual property and rights (IP&R) and intangible asset financial services firm. We provide the technical and financial systems that allow public and private markets to use IP&R and IA for regulated transactions in banking, securities, insurance, and public innovation investment and technology procurement. From our pioneering work in creating the world’s first standards-based innovation collateralization financial products for banking and securities to our work in grassroots innovator enablement and patent quality assurance programs, M·CAM provides the mechanism to balance the interests of public and commercial sectors to support and build thriving economies.

The M·CAM Patently Obvious® report on iBio, Inc. can be found HERE.